AIDS: The AIDS Vaccine Evaluation Group (AVEG) has begun enrollment in three new clinical trials that are testing a novel route of immunization (AVEG 027), an innovative vaccine strategy (AVEG 028), and a new adjuvant, or vaccine booster (AVEG 033). AVEG 027 is studying an experimental vaccine being applied topically to specific mucosal sites and then measuring the antibodies created at those sites. Since HIV is often transmitted across mucosal surfaces, it is believed a vaccine that induces mucosal antibodies will work better than other types of vaccines. AVEG 028 uses a weakened form of Salmonella bacteria (a bacteria that reproduces exclusively in human cells) to present an HIV protein to the immune system and induce immune responses. Finally, AVEG 033 combines GM-CSF with a canarypox virus-based vector containing HIV genes to determine if GM-CSF can improve the immune response to the vector. Additional information on each trial is provided.